Imperial College London

Dr Ning Wang

Faculty of MedicineDepartment of Surgery & Cancer

Research Associate







ICTEM buildingHammersmith Campus





I completed my PhD in medicinal chemistry with Prof Eric Aboagye, Dr Louis Allott and Dr Diana Brickute at Imperial College London, where I developed targeted choline kinase alpha (CHKA) inhibitors via prodrug and peptide receptor targeting strategies. I am currently working with Prof Eric Aboagye and Prof Ramon Vilar as a Research Associate; My project aims to develop Pt-mediated theragnostic platforms that target DNA/RNA.

My main research interests are developing novel diagnostic (radiotracers for PET imaging) and therapeutic reagents (kinase inhibitors, Pt complexes and antibody drug conjugates) for cancer treatment, using chemistry tools such as bioorthogonal chemistry and bioconjugation.




Aboagye E, Teh JH, Amgheib A, et al., 2023, Evaluation of [18F]AlF-EMP-105 for molecular imaging of 2 C-Met, Pharmaceutics, Vol:15, ISSN:1999-4923, Pages:1-13

Aboagye E, Brickute D, Allott L, et al., 2022, Design, synthesis, and evaluation of a novel PET imaging agent targeting lipofuscin in senescent cells, Rsc Advances: an International Journal to Further the Chemical Sciences, Vol:12, ISSN:2046-2069, Pages:26372-26381

Aboagye E, Li Y, Inglese M, et al., 2021, Consideration of metabolite efflux in radiolabelled choline kinetics, Pharmaceutics, Vol:13, ISSN:1999-4923, Pages:1-18

Aboagye E, Wang N, Brickute D, et al., 2021, Novel non-congeneric derivatives of the choline kinase alpha inhibitor ICL-CCIC-0019, Pharmaceutics, Vol:13, ISSN:1999-4923, Pages:1-17

Allott L, Chen C, Braga M, et al., 2021, Detecting hypoxia in vitro using 18F-pretargeted IEDDA “click” chemistry in live cells, Rsc Advances: an International Journal to Further the Chemical Sciences, Vol:11, ISSN:2046-2069, Pages:20335-20341

More Publications